- Home
- ASTC vs IMNN Comparison
ASTC vs IMNN Comparison
Compare ASTC & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASTC
- IMNN
- Stock Information
- Founded
- ASTC 1984
- IMNN 1982
- Country
- ASTC United States
- IMNN United States
- Employees
- ASTC N/A
- IMNN N/A
- Industry
- ASTC Biotechnology: Laboratory Analytical Instruments
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- ASTC Industrials
- IMNN Health Care
- Exchange
- ASTC Nasdaq
- IMNN Nasdaq
- Market Cap
- ASTC 9.8M
- IMNN 12.1M
- IPO Year
- ASTC 1995
- IMNN 1985
- Fundamental
- Price
- ASTC $5.65
- IMNN $0.77
- Analyst Decision
- ASTC
- IMNN Buy
- Analyst Count
- ASTC 0
- IMNN 2
- Target Price
- ASTC N/A
- IMNN $14.00
- AVG Volume (30 Days)
- ASTC 8.4K
- IMNN 2.3M
- Earning Date
- ASTC 05-13-2025
- IMNN 08-13-2025
- Dividend Yield
- ASTC N/A
- IMNN N/A
- EPS Growth
- ASTC N/A
- IMNN N/A
- EPS
- ASTC N/A
- IMNN N/A
- Revenue
- ASTC $903,000.00
- IMNN N/A
- Revenue This Year
- ASTC N/A
- IMNN N/A
- Revenue Next Year
- ASTC N/A
- IMNN N/A
- P/E Ratio
- ASTC N/A
- IMNN N/A
- Revenue Growth
- ASTC N/A
- IMNN N/A
- 52 Week Low
- ASTC $5.39
- IMNN $0.37
- 52 Week High
- ASTC $12.29
- IMNN $3.65
- Technical
- Relative Strength Index (RSI)
- ASTC 44.61
- IMNN 40.86
- Support Level
- ASTC $5.50
- IMNN $0.70
- Resistance Level
- ASTC $5.86
- IMNN $0.86
- Average True Range (ATR)
- ASTC 0.30
- IMNN 0.10
- MACD
- ASTC -0.02
- IMNN -0.05
- Stochastic Oscillator
- ASTC 16.96
- IMNN 10.34
About ASTC Astrotech Corporation (DE)
Astrotech Corp is a science and technology development company. The firm invents, acquires, and commercializes technological innovations sourced from internal research, universities, laboratories, and research institutions. The 1st Detect develops, manufactures, and sells chemical analyzers for use in the airport security, military, and breath analysis markets. AgLAB develops a series of mass spectrometers for use in the agriculture market.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).